Building access to healthcare in rural India: possibility and feasibility of low‐cost medicine

Abstract

Purpose -The purpose of this paper is to evaluate the possibility of marketing specific low-cost drugs across segmented markets in India. Design/methodology/approach -The study is empirical in nature, based on the primary data gathered through actual field survey. The study analyzes the attitudes, perceptions and experiences of five stockists, 50 physicians and 100 patients drawn from 20 healthcare organizations from different parts of the State of Karnataka in India. Findings -The survey findings revealed that patients would be happy and would have better access to medicine if the same is offered at a lower price. Doctors are willing to prescribe generic drugs. Generic drug market has good economic feasibility. At present, the consumption of generic drugs to branded drugs in hospitals is found to be in the ratio 2:3 while for the stockist it is in the ratio 1:2. The study also revealed the fact that patients prefer to take generic medicines mostly on the basis of physicians' advice. They do consider cost but generally go by the prescriptions of the doctors. Practical implications -Prescribing generic drugs would definitely contribute to greater use of medicine by the rural poor and thus better health conditions in rural areas. Low-cost medicine is an opportunity for pharmaceutical companies because consumers of healthcare are increasingly concerned with the quality and the cost of drugs that they buy. This research enhances sales and marketing management in terms of creating awareness of the importance of doctors' perceptions. Healthcare providers would benefit from the findings of this paper. Originality/value -As the generic drug market encompasses a variety of healthcare professionals and users, this paper establishes a practical methodology to have an understanding about the attitudes, perceptions and experiences of stockists, physicians and patients regarding the usage of such low-cost drugs.

Consumer Sovereignty in Healthcare: Fact or Fiction?

“…The study results cast doubt on the basic premise that cost sharing inspires patients to economize wisely. Ironically, the same study was able to find evidence in support of the fact that not all patients are motivated to economize, only poor patients do (Dongre et al, 2010).…”

“…Here, healthcare service quality is defined as the consumer's judgment about a healthcare product's overall functional superiority or excellence, and price refers to what is given up or sacrificed to obtain the healthcare product (Reidenbach and SadiferSmallwood, 1990;Zeithaml, 1988). Healthcare costs and prices are often used interchangeably (Dongre et al, 2010;Marshall et al 2009), and healthcare costs affect patients' access to care (Lagnada and Tanouye, 2001) as well as patients' personal finances (Gleckman, 2006). Intuitively, a basic question must be answered before consumer sovereignty can be accepted as the benchmark of ethics in the healthcare industry.…”

Who Benefits from Pharmaceutical Price Controls? Evidence from India

“…Columns (2) and (4) show that market concentration does not have a significant impact on firms' decisions to exit after the legislation. Though local firms are of mixed reputation and quality, they produce low-priced medicines that are important for consumer access -particularly for consumers who are poor or live in rural areas (Dongre et al, 2010). The most price-sensitive consumers, who depend on these low-cost products, may be negatively impacted by the exit of local firms.…”

CRM Index Development and Validation in Indian Hospitals

“…Tucker and Adams (2001) integrative patient evaluation model shows how empathy, reliability, caring, responsiveness, communication, access and outcome dimensions predict satisfaction and quality as moderated by the patient's socio-demographic characteristics. The recent studies done in healthcare have a prime focus on quality, value and satisfaction (Naidu, 2009;Padma et al, 2009;Aagja & Garg, 2010;Anand & Sinha, 2010;Chahal, 2010;Chahal & Kumari, 2010;Dongre et al, 2010;Mittal, 2010;Narang, 2010;Padma et al, 2010;Parish & Holloway, 2010;Chahal & Kumari, 2011;York & McCarthy, 2011).…”